Neuroscience

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped…

5 months ago

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents

Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes datasetMALVERN,…

5 months ago

BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025

BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

5 months ago

Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics

• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease…

5 months ago

AI in Telehealth & Telemedicine Market worth $27.14 Billion by 2030 with 36.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ -- The global AI in Telehealth & Telemedicine Market, valued at US$2.85 billion…

5 months ago

Creyos Featured in Alzheimer’s Research at AAIC 2025

Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital…

5 months ago

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs…

5 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b…

5 months ago

Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke

The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of…

5 months ago

Red Light Holland Reports 2025 Audited Year-End Results – Demonstrates Continued Fiscal Discipline, Strategic Growth, and Psilocybin R&D Expansion

Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…

5 months ago